SG11202109645QA - Methods of treating al amyloidosis - Google Patents

Methods of treating al amyloidosis

Info

Publication number
SG11202109645QA
SG11202109645QA SG11202109645QA SG11202109645QA SG 11202109645Q A SG11202109645Q A SG 11202109645QA SG 11202109645Q A SG11202109645Q A SG 11202109645QA SG 11202109645Q A SG11202109645Q A SG 11202109645QA
Authority
SG
Singapore
Prior art keywords
amyloidosis
treating
methods
Prior art date
Application number
Inventor
Gene Kinney
Wagner Zago
Carol Karp
Radhika Tripuraneni
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of SG11202109645QA publication Critical patent/SG11202109645QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
    • A61B5/1124—Determining motor skills
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—3D [Three Dimensional] image rendering
    • G06T15/06—Ray-tracing
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—3D [Three Dimensional] image rendering
    • G06T15/50—Lighting effects
    • G06T15/506—Illumination models
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/026—Measuring blood flow
    • A61B5/029—Measuring or recording blood output from the heart, e.g. minute volume
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG11202109645Q 2019-03-05 2020-03-05 Methods of treating al amyloidosis SG11202109645QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814252P 2019-03-05 2019-03-05
US201962942722P 2019-12-02 2019-12-02
PCT/IB2020/000186 WO2020178638A1 (en) 2019-03-05 2020-03-05 Methods of treating al amyloidosis

Publications (1)

Publication Number Publication Date
SG11202109645QA true SG11202109645QA (en) 2021-10-28

Family

ID=70476256

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109645Q SG11202109645QA (en) 2019-03-05 2020-03-05 Methods of treating al amyloidosis

Country Status (16)

Country Link
US (2) US11692024B2 (en)
EP (1) EP3934689A1 (en)
JP (1) JP2022522889A (en)
KR (1) KR20220019656A (en)
CN (1) CN113811332A (en)
AU (1) AU2020231081A1 (en)
BR (1) BR112021017550A2 (en)
CA (1) CA3132780A1 (en)
CL (1) CL2021002318A1 (en)
FR (1) FR3111560B1 (en)
IL (1) IL286040A (en)
JO (1) JOP20210245A1 (en)
MA (1) MA55209A (en)
MX (1) MX2021010665A (en)
SG (1) SG11202109645QA (en)
WO (1) WO2020178638A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023541191A (en) * 2020-09-14 2023-09-28 ケーラム バイオサイエンシーズ， インコーポレイテッド How to treat amyloidosis
TW202332465A (en) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 Methods of treating al amyloidosis
WO2023137342A2 (en) * 2022-01-11 2023-07-20 Prothena Biosciences Limited Methods of treating al amyloidosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
CA2555185C (en) 2004-02-06 2020-03-24 Morphosys Ag Anti-cd38 human antibodies and uses therefor
EA015584B1 (en) 2005-03-23 2011-10-31 Генмаб А/С Antibody to human cd38 and use thereof
EA028356B1 (en) 2007-12-28 2017-11-30 Протена Байосайенсиз Лимитед Treatment and prophylaxis of amyloidosis
JP6093696B2 (en) 2010-06-09 2017-03-08 ゲンマブ エー／エス Antibody against human CD38
JP6431372B2 (en) 2011-10-25 2018-11-28 プロシーナ バイオサイエンシーズ リミテッド Antibody formulations and methods
US9364542B2 (en) 2011-10-28 2016-06-14 Excelse Bio, Inc. Protein formulations containing amino acids
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
JP6827426B2 (en) 2015-05-20 2021-02-10 ヤンセン バイオテツク，インコーポレーテツド Anti-CD38 antibody for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
LT3827845T (en) 2015-11-03 2022-06-10 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
WO2018005967A1 (en) * 2016-06-30 2018-01-04 Prothena Therapeutics Limited Compositions for treating amyloidosis
US11382974B2 (en) * 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
US20200002410A1 (en) 2018-06-28 2020-01-02 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
KR20210143752A (en) 2019-02-12 2021-11-29 프로테나 바이오사이언시즈 리미티드 Treatment of AL amyloidosis using a combination of monoclonal antibodies against the CD38 cell membrane molecule and immunoglobulin light chain on antibody-producing cells and other immune cells

Also Published As

Publication number Publication date
CL2021002318A1 (en) 2022-05-06
EP3934689A1 (en) 2022-01-12
WO2020178638A1 (en) 2020-09-10
MX2021010665A (en) 2021-12-10
BR112021017550A2 (en) 2021-11-09
FR3111560A1 (en) 2021-12-24
IL286040A (en) 2021-10-31
MA55209A (en) 2022-01-12
CA3132780A1 (en) 2020-09-10
FR3111560B1 (en) 2024-03-22
KR20220019656A (en) 2022-02-17
CN113811332A (en) 2021-12-17
JOP20210245A1 (en) 2023-01-30
US11692024B2 (en) 2023-07-04
AU2020231081A1 (en) 2021-09-30
US20200308260A1 (en) 2020-10-01
US20230331831A1 (en) 2023-10-19
JP2022522889A (en) 2022-04-20

Similar Documents

Publication Publication Date Title
IL280919A (en) Methods of treating aging-related disorders
SG11202010830WA (en) Methods of treating phenylketonuria
IL286040A (en) Methods of treating al amyloidosis
IL285110A (en) Methods of treating multiple myeloma
IL288612A (en) Treatments of angioedema
IL277379A (en) Methods of treating ttr amyloidosis using ag10
ZA202203776B (en) Methods of treating epilepsy using the same
IL283337A (en) Methods of treating whsc1-overexpressing cancers by inhibiting setd2
IL278759A (en) Method of treating major depressive disorder
SG11202112232YA (en) Methods of treating neuropathy
IL292678A (en) Methods of treating depressive disorders
SG11202107017TA (en) Methods of treating cancer
IL287210A (en) Method of treating tumours
IL287130A (en) Methods of treating pruritus
IL284797A (en) Methods of treating addiction
IL285822A (en) Methods of treating organic acidemias
SG11202105877YA (en) Method of treatment
IL268111A (en) Methods of treating pain
GB201907305D0 (en) Treatment of conditions
IL304755A (en) Methods of treating al amyloidosis
IL289824A (en) Methods of treating multiple sclerosis
IL290983A (en) Methods of treatment
GB201918853D0 (en) Methods of treatment
GB201900942D0 (en) Methods of treatment
IL287250A (en) Method of treatment